Tci Wealth Advisors, Inc. Alaunos Therapeutics, Inc. Transaction History

Tci Wealth Advisors, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 29, 2021	SELL	$2.82 - $5.6 $1,128 - $2,240	-400 Reduced 36.36%	700 $3,000
Q4 2020 Jan 21, 2021	SELL	$2.09 - $3.09 $418 - $618	-200 Reduced 15.38%	1,100 $3,000
Q1 2020 Apr 14, 2020	SELL	$1.9 - $4.98 $1,520 - $3,984	-800 Reduced 38.1%	1,300 $3,000
Q4 2019 Jan 27, 2020	BUY	$3.95 - $5.35 $395 - $535	100 Added 5.0%	2,100 $10,000
Q2 2019 Jul 23, 2019	SELL	$3.98 - $6.2 $1,990 - $3,100	-500 Reduced 20.0%	2,000 $12,000
Q1 2019 Apr 11, 2019	BUY	$2.0 - $4.4 $800 - $1,760	400 Added 19.05%	2,500 $10,000
Q4 2018 Jan 17, 2019	SELL	$1.61 - $3.62 $644 - $1,448	-400 Reduced 16.0%	2,100 $4,000
Q3 2018 Nov 02, 2018	SELL	$2.26 - $3.27 $1,355 - $1,962	-600 Reduced 19.35%	2,500 $8,000
Q2 2018 Jul 27, 2018	SELL	$3.02 - $4.94 $2,718 - $4,446	-900 Reduced 22.5%	3,100 $9,000
Q1 2018 Apr 30, 2018	SELL	$3.46 - $5.14 $4,498 - $6,682	-1,300 Reduced 24.53%	4,000 $16,000
Q4 2017 Feb 01, 2018	SELL	$4.0 - $6.54 $3,600 - $5,886	-900 Reduced 14.52%	5,300 $22,000
Q3 2017 Oct 24, 2017	SELL	$4.99 - $6.57 $3,493 - $4,599	-700 Reduced 10.14%	6,200 $38,000
Q2 2017 Aug 10, 2017	BUY	N/A	6,900	6,900 $43,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $422M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.